Table 2 The relationship between CONUT score and clinicopathological characteristics of the patients
Variable | Total(n = 278) | CONUT score | χ2 | P | |
|---|---|---|---|---|---|
< 3(n = 164) | ≥ 3(n = 114) | ||||
Gender | 0.742 | 0.389 | |||
Male | 192(69.1%) | 110(67.1%) | 82(71.9%) | ||
Female | 86(30.9%) | 54(32.9%) | 32(28.1%) | ||
Age | 8.537 | 0.003 | |||
< 60 | 109(39.2%) | 76(46.3%) | 33(28.9%) | ||
≥ 60 | 169(60.8%) | 88(53.7%) | 81(71.1%) | ||
Smoking status | 1.276 | 0.259 | |||
Minimal/never | 116(41.7%) | 73(44.5%) | 43(37.7%) | ||
Current/former | 162(58.3%) | 91(55.5%) | 71(62.3%) | ||
ECOG-PS | 5.623 | 0.018 | |||
0/1 | 160(57.6%) | 104(63.4%) | 56(49.1%) | ||
2 | 118(42.4%) | 60(36.6%) | 58(50.9%) | ||
Histology subtype | 3.272 | 0.195 | |||
Squamous | 113(40.6%) | 60(36.6%) | 53(46.5%) | ||
Adenocarcinoma | 133(47.8%) | 82(50.0%) | 51(44.7%) | ||
others | 32(11.5%) | 22(13.4%) | 10(8.8%) | ||
TNM staging | 7.504 | 0.006 | |||
III | 102(36.7%) | 71(43.3%) | 31(27.2%) | ||
IV | 176(63.3%) | 93(56.7%) | 83(72.8%) | ||
Chemotherapy regimens | 5.691 | 0.233 | |||
DP | 32(11.5%) | 17(10.4%) | 15(13.2%) | ||
GP | 97(34.9%) | 55(33.5%) | 42(36.8%) | ||
NP | 37(13.3%) | 23(14.0%) | 14(12.3%) | ||
PC | 83(29.9%) | 56(34.1%) | 27(23.7%) | ||
TP | 29(10.4%) | 13(7.9%) | 16(14.0%) | ||
CEA | 0.764 | 0.382 | |||
Normal | 123(44.2%) | 69(42.1%) | 54(47.4%) | ||
High | 155(55.8%) | 95(57.9%) | 60(52.6%) | ||
CYF | 0.750 | 0.386 | |||
Normal | 76(27.3%) | 48(29.3%) | 28(24.6%) | ||
High | 202(72.7%) | 116(70.7%) | 86(75.4%) | ||
NSE | 0.638 | 0.424 | |||
Normal | 153(55.0%) | 87(53.0%) | 66(57.9%) | ||
High | 125(45.0%) | 77(47.0%) | 48(42.1%) | ||
SII | 30.353 | 0.000 | |||
< 984.72 | 140(50%) | 60(37%) | 80(70%) | ||
≥ 984.72 | 138(50%) | 104(63%) | 34(30%) | ||
PNI | 53.448 | 0.000 | |||
≥ 48.95 | 129(46%) | 106(64.0%) | 23(20%) | ||
< 48.95 | 149(54%) | 58(36.0%) | 91(80%) | ||